Modulation of Th2 responses by peptide analogues in a murine model of allergic asthma: Amelioration or deterioration of the disease process depends on the Th1 or Th2 skewing characteristics of the therapeutic peptide

Journal of Immunology

Volumn 164, Issue 2, 2000, Pages 580-588

  Janssen, Edith M ^a,b   Van Oosterhout, Antoon J M ^b   Van Rensen, Annemiek J M L ^b   Van Eden, Willem ^a   Nijkamp, Frans P ^b   Wauben, Marca H M ^a,b  

^a Department of Infectious Diseases and Immunology   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGEN; CYTOKINE; GAMMA INTERFERON; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; LIPOSOME; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; OVALBUMIN; SYNTHETIC PEPTIDE;

ALLERGIC ASTHMA; ANIMAL CELL; ANIMAL MODEL; ARTICLE; ASTHMA; FLOW CYTOMETRY; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOTHERAPY; INFLAMMATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SENSITIZATION; T LYMPHOCYTE ACTIVATION;

EID: 0034650788     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.164.2.580     Document Type: Article

References (48)

1. Swain, S. L., A. D. Weinberg, M. English, and G. Huston. 1990. IL-4 directs the development of Th2-like helper effectors. J. Immunol. 145:3796.
2. Del Prete, G., E. Maggi, P. Paola, I. Ghretien, A. Tiri, D. Macchia, J. Banchereau, J. E. de Vries, and S. Romagnani. 1988. IL-4 is an essential factor for the IgE synthesis induced in vitro by human T cell clones and their supernatant. J. Immunol. 140:4193.
3. Zurawski, G., and J. E. de Vries. 1994. Interleukin 13, an interleukin 4-like cytokine that acts on monocytes and B cells, but not on T cells, Immunol. Today 15:19.
4. Warringa, R. A. J., R. C. Schwiezer, T. Maikoe, P. L. B. Bruijnzeel, and L. Koenderman. 1992. Modulation of eosinophil chemotaxis by interleukin-5. Am. J. Respir. Cell Mol. Biol. 7:631.
5. Simon, H. U., and K. Blaser. 1995. Inhibition of programmed eosinophil death: a key pathogenic event for eosinophilia? Immunol. Today 16:53.
6. Corry, D. B., H. G. Folkesson, M. L. Warnock, D. J. Erle, M. A. Matthay, J. P. Wiener-Kronish, and R. M. Locksley. 1996. Interleukin 4, but not interteukin 5 or eosinophils, is required in a murine model of acute airway hyperreactivity. J. Exp. Med. 183:109.
7. Wilis-Karp, M., J. Luyimbazi, X. Xu, B. Schofield, T. Y. Neben, C. L. Karp, and D. D. Donaldson. 1998. Interleukin-13: central mediator of allergic asthma. Science 282:2258.
8. Ebner, C., U. Siemann, and B. Bohle. 1997. Immunological changes during specific immunotherapy of grass pollen allergy: reduced lymphoproliferative response to allergen and shift from Th2 to Th1 in T cell clones specific for Ph1 p I, a major grass pollen allergen. Clin. Exp. Allergy 27:1007.
9. + T cells from allergic individuals. J. Exp. Med. 178:2123.
10. Akdis, C. A., M. Akdis, T. Blesken, D. Wymann, S. S. Alkan, U. Müller, and K. Blaser. 1996. Epitope specific tolerance to Phospholipase A2 in bee venom immunotherapy and recovery by IL-2 and IL-15 in vitro. J. Clin. Invest. 98:1676.
11. Bousquet, J., and F. B. Michel. 1994. Specific immunotherapy in asthma: is it effective? J. Allergy Clin. Immunol. 94:1.
12. Greidener, D. K. 1996. Risk management in allergen immunotherapy. J. Allergy Clin. Immunol. 98:S330-334.
13. Bousquet, J., A. Hejjaoui, H. Dhivert, A. M. Clauzel, and F. B. Michel. 1989. Immunotherapy with a standardized Dermotophagoides pteronyssinus extract: systemic reactions during the rush protocol in patients suffering from asthma. J. Allergy Clin. Immunol. 83:797.
14. Oshiba, A., E. Hamelmann, K. L. Bradley, J. E. Loader, H. Renz, G. L. Larsen, and E. W. Gelfand. 1996. Pretreatment with allergen prevents immediate hypersensitivity and airway hyperresponsiveness. Am. J. Respir. Crit. Care Med. 153: 102.
15. Müller, U., C. A. Akdis, M. Fricker, M. Akdis, T. Blesken, F. Bettens, and K. Blaser. 1998. Successful immunotherapy with T-cell epitope peptides of bee venom Phospholipase A2 induces specific T-cell anergy in patients allergic to bee venom. J. Allergy Clin. Immunol. 101:747.
16. Norman, P. S., J. L. Ohman, A. A. Long, P. S. Creticos, M. A. Gefter, Z. Shaked, R. A. Wood, P. A. Eggleston, K. B. Hafner, P. Rao, et al. 1996. Treatment of cat allergy with T-cell reactive peptides. Am. J. Respir. Crit. Care Med. 154:1623.
17. Marcotte, G. V., C. M. Braun, P. S. Norman, C. F. Nicodemus, A. Kagey-Sobotka, L. M. Lichtenstein, and D. M. Essayan. 1998. Effects of peptide therapy on ex vivo T-cell responses. J. Allergy Clin. Immunol. 101:506.
18. Janssen, E. M., M. H. M. Wauben, E. H. Jonker, G. Hofman, W. van Eden, F. P. Nijkamp, and A. J. M. van Oosterhout. 1999. Opposite effects of immunotherapy with ovalbumin and the immunodominant T cell epitope on airway eosinophilia and hyperresponsiveness in a murine model of allergic asthma. Am. J. Respir. Cell Mol. Biol. 21:21.
19. Evavold, B. D., and P. M. Allen. 1991. Separation of IL-4 production from T cell proliferation by an altered T cell receptor ligand. Science 252:1308.
20. + T cells into Th1 and Th2 subsets. J. Immunol. 159:5802.
21. Sloan-Lancaster, J., B. D. Evavold, and P. M. Allen. 1994. Th2 cell clonal anergy as a consequence of partial activation. J. Exp. Med. 180:1195.
22. La Face, D. M., C. Couture, K. Anderson, G. Shih, J. Alexander, A. Sette, T. Mustelin, A. Altman, and H. M. Grey. 1997. Differential T cell signaling induced by antagonist peptide-MHC complexes and the associated phenotypic responses. J. Immunol. 158:2057.
23. Hessel, E. M., A. J. M. van Oosterhout, C. L. Hofstra, J. J. de Bie, J. Garssen, H. van Loveren, A. K. C. P. Verheyen, H. F. J. Savelkoul, and F. P. Nijkamp. 1995. Bronchoconstriction and airway hyperresponsiveness after ovalbumin inhalation in sensitized mice. Eur. J. Pharmacol. 293:401.
24. Hofstra, C. L., I. van Ark, G. Hofman, M. Kool, F. P. Nijkamp, and A. J. M. van Oosterhout. 1998. Prevention of Th2-like cell responses by coadministration of IL-12 and IL-18 is associated with inhibition of antigen-induced airway hyperresponsiveness, eosinophilia, and serum IgE levels. J. Immunol. 161:5054.
25. van der Zee, R., S. M. Anderton, C. A. F. Buskens, E. Alonsode Velasco, and W. van Eden. 1995. Heat shock protein T cell epitopes as immunogenic carriers in subunit vaccines. In Peptides 1994: Proceedings of the Twenty-Third European Peptide Symposium. H. L. S. Maia, ed., ESCOM, Leiden, The Netherlands, pp. 841-842.
26. low thymocytes in vivo. Science 250: 1720.
27. Joosten, I., M. H. M. Wauben, M. C. Holewijn, K. Reske, L. O. Pedersen, C. F. Roosenboom, E. J. Hensen, E. van Eden, and S. Buus. 1994. Direct binding of autoimmune disease related T cell epitopes to purified Lewis rat MHC class II molecules. Int. Immunol. 6:751.
28. Kappler, J. W., B. Skidmore, J. White, and P. Marrack. 1981. Amigen-inducible, H-2-restricted, interleukin-2-producing T cell hybridomas: lack of independent antigen and H-2 recognition. J. Exp. Med. 153:1198.
29. Coffman, R. L. 1982. Surface antigen expression and immunoglobulin gene rearrangement during mouse pre-B cell development. Immunol. Rev. 69:5.
30. Unkeless, J. C. 1979. Characterization of a monoclonal antibody directed against mouse macrophage and lymphocyte Fc receptors. J. Exp. Med. 150:580.
31. Haskins, K., R. Kubo, J. White, M. Pigeon, J. Kappler, and P. Marrack. 1983. The major histocompatibility complex-restricted antigen receptor on T cells. I. Isolation with a monoclonal antibody. J. Exp. Med. 175:1149.
32. Villee, D. B., and M. L. Powers. 1977. Long term culture of tumour-specific cytotoxic T cells. Nature 268:154.
33. 't Hart, B. A., D. G. Elferink, J. W. Drijfhout, G. Storm, L. van Blooijs, R. E. Bontrop, and R. R. de Vries. 1997. Liposome-mediated peptide loading of MHC-DR molecules in vivo. FEBS Lett. 409:91.
34. van Oosterhout, A. J. M., B. van Esch, G. Hofman, C. L. Hofstra, I. van Ark, F. P. Nijkamp, M. L. Kapsenberg, H. F. J. Savelkoul, and F. R. Weller. 1998. Allergen immunotherapy inhibits airway eosinophilia and hyperresponsiveness associated with decreased IL-4 production by lymphocytes in a murine model of allergic asthma. Am. J. Respir. Cell Mol. Biol. 19:622.
35. Kumar, V., V, Bhardwaj, L. Soares, J. Alexander, A. Sette, and E. Sercarz. 1995. Major histocompatibility complex binding affinity of an antigenic determinant is crucial for the differential secretion of interleukin 4/5 or interferon γ by T cells. Proc. Natl. Acad. Sci. USA 92:9510.
36. Pfeiffer, C., J. Stein, S. Southwood, H. Ketelaar, A. Sette, and K. Bottomly. 1995. Altered peptide ligands can control T lymphocyte differentiation in vivo. J. Exp. Med. 181:1569.
37. Lyons, D. S., S. A. Lieberman, J. Hampl, J. J. Boniface, Y. Chien, L. J. Berg, and M. M. Davis. 1996. A TCR binds to antagonist ligands with lower affinities and faster dissociation rates than to agonists. Immunity 5:53.
38. Kersh, G. J., E. N. Kersh, D. H. Fremont, and P. M. Allen. 1998. High- and low-potency ligands with similar affinities for the TCR: the importance of kinetics in TCR signaling. Immunity 9:817.
39. + T cells by anligenic peptides altered for TCR binding. J. Immunol. 158:4237.
40. Sette, A., S. Buus, S. Colon, J. A. Smith, C. Miles, and H. M. Grey. 1987. Structural characteristics of an antigen required for its interaction with Ia and recognition by T cells. Nature 328:395.
41. Scott, C. A., P. A. Peterson, L. Teyton, and I. A. Wilson. 1998. Crystal structures of two I-Ad-peptide complexes reveal that high affinity can be achieved without large anchor residues. Immunity 8:319.
42. Korsgren, M., J. S. Erjefält, O. Korsgren, F. Sundler, and C. G. A. Persson. 1997. Allergic eosinophil-rich inflammation develops in lungs and airways of B cell deficient mice. J. Exp. Med. 185:885.
43. Mehlhop, P. D., M. Rijn, A. B. Goldberg, J. P. Brewer, V. P. Kurup, T. R. Mertin, and H. C. Oettgen. 1997. Allergen-induced bronchial hyperreactivity and eosinophilic inflammation occur in the absence of IgE in a mouse model of asthma. Proc. Natl. Acad. Sci. USA 94:1344.
44. Hofstra, C. L., I. van Ark, G. Hofman, F. P. Nijkamp, P. M. Jardieu, and A. J. M. van Oosterhout. 1998. Differential effects of andogenous and exogenous interferon-γ on immunoglobulin E, cellular infiltration, and airway responsiveness in a murine model of allergic asthma. Am. J. Respir. Cell Mol. Biol. 19:826.
45. Lack, G., H. Renz, J. Saloga, K. L. Bradley, J. Loader, D. Y. Leung, G. Larsen, and E. W. Gelfand. 1994. Nebulized but not parenteral IFN-γ decreases IgE production and normalizes airway function in a murine model of allergen sensitization. J. Immunol. 152:2546.
46. Iezzi, G., K. Karjalainen, and A. Lanzavecchia. 1998. The duration of antigenic stimulation determines the fate of naive and effector T cells. Immunity 8:89.
47. + T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 389:737.
48. Akdis, C. A., T. Blesken, M. Akdis, B. Wüthrich, and K. Blaser. 1998. Role of IL-10 in specific immunotherapy. J. Clin. Invest. 102:98.